Product Information
ZUBSOLV 11.4-2.9 MG TABLET SL is a brand product labeled by Orexo US, Inc., priced at $21.0479 per EA under NDC 54123011430. Its NADAC has been published 472 times since Sep 20, 2017.
FDA first approved this application on Jul 3, 2013.
Strength
11.4; 2.9 mg/1; mg/1
Manufacturer
Orexo US, Inc.NDC
54123011430
Classification
Brand
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
SUBLINGUAL
Effective Date
9/23/2026
Active Ingredients
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA204242FDA Approved
7/3/2013
On Market Since
12/11/2014
Pharmacological Classes
Price Statistics
The NADAC for ZUBSOLV 11.4-2.9 MG TABLET SL has been published 472 times since Sep 20, 2017, and over the history we have for it it has risen 39.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $21.0479 per EA |
|---|---|
| All-time high | $21.1353 (May 13, 2026) |
| All-time low | $15.0880 (Sep 20, 2017) |
| 52-week high | $21.1353 |
| 52-week low | $20.3055 |
| Median price | $18.0924 |
| Average price | $18.1476 |
| Largest weekly change | +6.0% (Jan 10, 2018) |
| Weeks tracked | 472 |
| Tracking since | Sep 20, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the buprenorphine hydrochloride and naloxone hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Orexo US, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
buprenorphine hydrochloride and naloxone hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ZUBSOLV 11.4-2.9 MG TABLET SL?
The current National Average Drug Acquisition Cost (NADAC) for ZUBSOLV 11.4-2.9 MG TABLET SL, manufactured by Orexo US, Inc., is $21.0479 per EA (NDC 54123011430), effective Sep 30, 2026.
How has the price of ZUBSOLV 11.4-2.9 MG TABLET SL changed over time?
Over the history we have for it, the NADAC for ZUBSOLV 11.4-2.9 MG TABLET SL has risen 39.5%. It has been tracked across 472 weekly CMS publications since Sep 20, 2017.
What are the highest and lowest recorded NADAC prices for ZUBSOLV 11.4-2.9 MG TABLET SL?
Since Sep 20, 2017, the NADAC for ZUBSOLV 11.4-2.9 MG TABLET SL has ranged from a low of $15.0880 (Sep 20, 2017) to a high of $21.1353 (May 13, 2026), with a median of $18.0924 per EA.
Are there cheaper alternatives to ZUBSOLV 11.4-2.9 MG TABLET SL?
No other NADAC-published product currently shares the active ingredient and strength of ZUBSOLV 11.4-2.9 MG TABLET SL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ZUBSOLV 11.4-2.9 MG TABLET SL?
ZUBSOLV 11.4-2.9 MG TABLET SL (NDC 54123011430) is labeled by Orexo US, Inc., and CMS classifies it as a brand product.